Evogene Announces Acute Graft-Versus-Host Disease As Target Indication For Its Internal Drug Discovery Program
Advancing a First-in-Class Small-Molecule Therapeutic, Guided by World-Leading Experts, to Address a Multi-Billion-Dollar Unmet Need in Steroid-Refractory PatientsREHOVOT, Israel, Oct. 28, 2026 /PRNewswire/ -- Evogene
Evogene is working on a new medicine for a serious disease called graft-versus-host disease. When a company targets a big medical problem that patients need help with, it shows ambition, but the medicine still needs to prove it actually works.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.